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Abstract
Corynebacterium striatum is an opportunistic pathogen, often multidrug-resistant, which has
been associated with serious infections in humans. Aminoglycosides are second-line or
complementary antibiotics used for the treatment of Corynebacterium infections. We investi-
gated the susceptibility to six aminoglycosides and the molecular mechanisms involved in
aminoglycoside resistance in a collection of 64 Corynebacterium striatum isolated in our lab-
oratory during the period 2005–2009. Antimicrobial susceptibility was determined using
E-test. The mechanisms of aminoglycoside resistance were investigated by PCR and
sequencing. The 64 C. striatum were assessed for the possibility of clonal spreading by
Pulsed-field Gel Electrophoresis (PFGE). Netilmicin and amikacin were active against the
64 C. striatum isolates (MICs90 = 0.38 and 0.5 mg/L, respectively). Twenty-seven of the 64
C. striatum strains showed a MIC90 for kanamycin > 256 mg/L, and 26 out the 27 were posi-
tive for the aph(3’)-Ic gene. Thirty-six out of our 64 C. striatum were streptomycin resistant,
and 23 out of the 36 carried both the aph(3”)-Ib and aph(6)-Id genes. The gene aac(3)-XI
encoding a new aminoglycoside 3-N acetyl transferase from C. striatum was present in 44
out of the 64 isolates, all of them showing MICs of gentamicin and tobramycin > 1 mg/L.
CS4933, a C. striatum showing very low susceptibility to kanamycin and streptomycin, con-
tains an aminoglycoside resistance region that includes the aph(3’)-Ic gene, and the tandem
of genes aph(3”)-Ib and aph(6)-Id. Forty-six major PFGE types were identified among the
64 C. striatum isolates, indicating that they were mainly not clonal. Our results showed that
the 64 clinical C. striatum were highly resistant to aminoglycosides and mostly unrelated.
Introduction
The genus Corynebacterium consists of more than 100 species (https://www.dsmz.de/bacterial-
diversity/prokaryotic-nomenclature-up-to-date, accessed November 18, 2016). Corynebacte-
rium spp. are widely distributed in the environment. Pathogenic Corynebacterium species
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include Corynebacterium diphtheriae and nondiphtheroid Corynebacterium. Nondiphtheroid
corynebacteria are part of the normal skin and mucous membranes microbiota of humans.
They have traditionally been considered as sample contaminants when isolated from clinical
stuffs. However, nondiphtheroid Corynebacterium are actually recognized as causing opportu-
nistic disease [1], particularly in specific circumstances, such as repeated exposure to broad-
spectrum antibiotics, after the use of invasive medical procedures or in patients who have suf-
fered long-term hospitalization [2,3,4]. Corynebacterium striatum has been implicated sporadi-
cally as etiological agent of a wide variety of infections, such as bacteraemia associated with
central venous catheters, arthritis, vertebral osteomyelitis, septicaemia, meningitis, endocardi-
tis, breast abscess, peritonitis, wound infections, and prosthetic joint infections [5], in both
immunocompetent and immunocompromised patients [3]. In two C. striatum outbreaks,
patient-to-patient transmission of a single C. striatum strain was reported [6,7].
Hospitals are “antibiotic-rich” environments, creating a selective pressure on the survival
of resistant bacteria by which resistance genes can be transferred to susceptible bacteria,
spreading multi-resistance. It has been suggested that this selective pressure favours the
overgrowth of C. striatum as a secondary colonizer in immunocompromised hosts [6], so
that C. striatum is considered a multi-resistant nosocomial pathogen [5]. In this context, the
emergence of multidrug resistant strains is of particular concern, because the therapeutic
options for the management of severely ill patients can be limited, increasing the reliance
on vancomycin, which is still active against practically all clinical isolates of the C. striatum.
Therapeutic efficacy of vancomycin can be improved if it is combined with a second antibi-
otic, most often an aminoglycoside. Thus, several cases of endocarditis due to C. striatum
were successfully treated with gentamicin combined with vancomycin [8,9]. Therefore,
aminoglycosides are considered as complementary antibiotics for the treatment of C. stria-
tum infections.
There is a need for more data from clinical isolates to evaluate the risk of emergence of anti-
microbial-resistant C. striatum strains and to track the transfer of resistance genes. In this
respect, we aimed to investigate the susceptibility to six aminoglycosides of 64 clinical isolates
of C. striatum from our sanitary area and characterized the molecular mechanisms of resis-
tance. The 64 C. striatum were typed by means of PFGE to inquire about their clonal relation-
ships and possible spread mechanisms.
Material and Methods
Bacterial strains and growth conditions
Sixty-four C. striatum obtained from clinical samples of 63 patients collected during the period
2005–2009 at the Clinical Microbiology laboratory of the Marque´s de Valdecilla University
Hospital, Santander, Spain, were included in this study. Only in one case, two isolates from the
same patient were included (C. striatum CS4108 and CS4489), since they showed different
PFGE patterns and MICs. The 64 C. striatum were isolated from surgical wound exudates (32),
non-surgical wound exudates (22, of which 7 were from diabetic foot lesions), blood (3),
abdominal drainage (1), peritoneal ascitic fluid (2), sputum (2), gluteus abscess (1), and
bronchoalveolar lavage fluid (1). They were grown on blood agar plates at 37˚C. All isolates
were identified as putative C. striatum using API CORYNE V2 strips (bioMe´rieux, Marcy
l’Etoile, France). C. striatum was differentiated from C. amycolatum using additional pheno-
typic tests (tyrosine hydrolysis, N-acetylglucosamine assimilation and phenylacetic acid assim-
ilation). Identification was confirmed by MALDI-TOF, using the Vitek-MSTM (bioMe´rieux)
system, according to manufacturer’s instructions.
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Susceptibility to aminoglycosides
The aminoglycosides used in this study were chosen because either they are frequently used in
clinical practice (amikacin, gentamicin, netilmicin, and tobramycin) or are good markers of
resistance mechanisms (kanamycin and streptomycin). MICs were determined using Etest1
(bioMe´rieux) on Mueller-Hinton agar (Pronadisa, Madrid, Spain), following the instructions
of the manufacturer. Clinical categories were established according to breakpoints defined by
the European Committee on Antimicrobial Susceptibility Testing (EUCAST) [10]. Since
EUCAST has only defined breakpoints for gentamicin, MIC values of amikacin, kanamycin,
netilmicin and tobramycin were interpreted according to EUCAST criteria for Staphylococcus
spp. The EUCAST lacks breakpoints of streptomycin for staphylococci and those for entero-
cocci are specified for detecting high-level resistance, which was not the primary objective of
this study. For this reason we have considered the MIC breakpoints values proposed by the
French Society of Microbiology (http://www.sfmmicrobiologie.org/UserFiles/files/casfm/
CASFM2013vjuin.pdf) to define the number of streptomycin sensitive, intermediate and resis-
tant strains. Staphylococcus aureus ATCC 29213 and Enterococcus faecalis ATCC 29212 were
used as control strains for susceptibility testing assays.
Pulsed-field gel electrophoresis and dendrogram analysis
PFGE was performed with a CHEF-DRIII system (Bio-Rad, Hercules, California, USA). Bacte-
ria were grown in Brain Heart Infusion agar (Pronadisa) with shaking at 37˚C for 48-72h. Cul-
tures were adjusted to A600 = 2.0, cells from 250 μl were pelleted and re-suspended in 300 μl of
TE buffer (10 mM Tris, 1 mM EDTA) containing 2 mg/ml lysozyme. This suspension was
incubated at 37˚C for 1 h, inverting the tubes every ten minutes. An equal volume of 2% LM
agarose (Pronadisa) in TE buffer containing 1% SDS and 0.2 mg/ml proteinase K was added,
and plugs were cast with a standard casting tray. After the plugs solidified, they were incubated
overnight at 55˚C with shaking in 4 ml of TE buffer containing 1% sarcosyl and 0.15mg/ml
proteinase K. The plugs were washed eight times with pre-warmed TE buffer and then digested
with 30 U of XbaI at 37˚C overnight. Electrophoresis was performed in a 1% agarose gel at 6
V/cm and 14˚C with 0.5xTBE buffer. Pulse times ramped from 0.1 to 5 seconds for 18h. Low
range PFGE marker (New England Biolabs, Beverly, USA) was used as the molecular size
marker. Cluster analysis was performed with Fingerprinting II v4.5 software (Bio-Rad,
Madrid, Spain) by using the Dice similarity coefficient and the unweighted pair Group method
with arithmetic means (UPGMA), with 1% of optimization and tolerance. Isolates were classi-
fied as indistinguishable if they showed 100% similarity, as closely related subtypes if they
showed 95–99% similarity, and as different strains if they showed<95% similarity.
Search of aminoglycoside resistance genes by PCR
The 64 C. striatum were screened for the presence of aminoglycoside modifying enzyme
(AME) genes common in gram-positive bacteria [aac(3)-XI, aph(2”)-Ia, aph(3’)-Ic, aph(3’)-
IIIa, aph(3”)-Ib, aph(6)-Id, ant(3”)-Ia, ant(4’)-Ia], or Enterobacteriae [ant(2”)-Ia, ant(4’)-IIa,
and aac(6’)-Ib] by PCR using primers specific for each gene (S1 Table) and by sequencing of
the PCR products. As a control, the 24 isolates susceptible to aminoglycosides were also used
in the PCR analysis. DNA was extracted using InstaGene matrix (Bio-Rad) according to man-
ufacturer’s instructions. Then, 10 μl of DNA template (10 pg/μl) was added to a reaction mix-
ture containing 4 U of Taq DNA polymerase (Bioline, London, United Kingdom), 1.5 mM
MgCl2, 5 μl of 10× PCR amplification buffer [160 mM (NH4)2 SO4, 670 mM Tris-HCl
(pH = 8.8), 0.1% Tween 20], 40 pmol of each primer, 0.2 mM each deoxynucleoside triphos-
phate (Bioline), and double-distilled water to a final volume of 50 μl. DNA was first denatured
Susceptibility to Aminoglycosides in Corynebacterium striatum
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at 95˚C for 5 min and then subjected to 30 cycles of amplification using a Perkin Elmer model
9600 thermal cycler under the following conditions: denaturation at 95˚C for 1 min, annealing
for 1 min, and extension at 72˚C for 1 min. After the final cycle, the reactions were terminated
by an extra run at 72˚C for 10 min, and the reaction products were then kept at 4˚C until anal-
ysis. Amplification products were characterized by electrophoresis in 1.5% agarose using 0.5x
TBE running buffer. PCR products were cleaned of amplification primer using the QIAquick
PCR Purification kit (Qiagen, Madrid, Spain) following the manufacturer’s instructions. Puri-
fied DNA was sequenced with the primers outlined in S1 Table.
Genome sequencing and analysis
C. striatum CS4933 whole DNA was prepared from cultures grown on blood agar plates
overnight. Bacterial cells were mixed with 2 ml of distilled water poured on the plate, trans-
ferred to a 2-ml Eppendorff tube, collected by centrifugation at 10,000g for 4 min, re-sus-
pended in 0.25 ml of Tris-EDTA buffer containing 20 mg of lysozyme/ml and 50 mg of
proteinase K/ml, and incubated at 37˚C for 1 h. Bacterial cells were then lysed by the addi-
tion of 0.25 ml of 0.1 M Tris containing 1% sodium dodecyl sulfate (SDS) and 400 μg/ml of
proteinase K and incubated at 55˚C for 1 h. The lysate was mixed with 0.1 ml of 5 M NaCl
and 100 μl of cetyltrimethylammonium bromide-NaCl and incubated at 65˚C for 10 min.
DNA was then extracted with chloroform-isoamyl alcohol and phenol-chloroform, precipi-
tated with isopropanol, and re-suspended gently in distilled water. For genomic sequencing
genomic libraries were prepared using the Illumina TruSeq DNA Sample Prep Kit and size-
selected to a 400 bp mean insert size using Sage Pippin Blue. Final libraries were sequenced
on a MiSeq platform using 250 base paired-end reads (v2 chemistry). Contigs were assem-
bled with the MacVector tool (http://macvector.com), and analysed using the NCBI ORF
finder (www.ncbi.nlm.nih.gov/gorf) and BLAST (www.ncbi.nlm.nih.gov/BLAST) tools.
The sequence of the C. striatum CS4933 region including aph(3’)-Ic, aph(3”)-Ib and aph(6)-
Id genes has been deposited in GenBank under accession number KP119857.
Results and Discussion
Susceptibility of C. striatum to aminoglycosides
According to the breakpoints previously indicated, 52 of the 64 C. striatum included in this
study were resistant to at least one of the six aminoglycosides, whereas the remaining 12 iso-
lates were aminoglycoside-susceptible. The MIC50 and MIC90 distributions of the different
aminoglycosides for the 64 C. striatum are presented in Table 1.
Considering the MIC90, netilmicin was the more active aminoglycoside against the C. stria-
tum we tested (MIC90 = 0.38 mg/L), followed by amikacin (MIC90 = 0.5 mg/L). All the isolates
were susceptible to these two compounds. Martı´nez-Martı´nez et al [11] have previously
reported that 27 out of 31 C. striatum were sensitive to amikacin. In this study, the activity of
gentamicin was lower than that of netilmicin and amikacin, with the MIC90 of gentamicin (8
mg/L) being 16 times higher than that of amikacin. Forty-five out of 64 isolates were resistant
to gentamicin. Other studies reported variable activity of gentamicin against C. striatum: Cam-
panile et al. [12] found a MIC90 of 32 mg/L for 36 C. striatum isolated in Italy whereas Go´mez-
Garce´s et al. [13] reported a MIC90 of 2 mg/L for a collection of 30 Spanish C. striatum. Tobra-
mycin was scarcely active against our C. striatum (MIC90 = 16 mg/L). The 45 isolates tobramy-
cin-resistant were resistant to gentamicin as well, suggesting a common mechanism involved
in resistance to these two compounds. Kanamycin and streptomycin showed poor activity
against our strains (MICs90 >256 and >1024 mg/L, respectively).
Susceptibility to Aminoglycosides in Corynebacterium striatum
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According to EUCAST criteria, six resistance profiles were found among the 52 C. striatum
isolates resistant to at least one of the tested aminoglycosides (Table 2). Forty-four of the 64
isolates were resistant to more than one of the tested aminoglycosides. The most frequently
encountered multi resistance phenotype was Kanamycin/Gentamicin/Tobramycin/Strepto-
mycin (n = 24), followed by Gentamicin/Tobramycin (n = 13). Furthermore, eight isolates
were resistant to just one of the considered aminoglycosides: seven to streptomycin and one to
kanamycin.
The data obtained in this study may support the consideration of netilmicin and amikacin
in combination with vancomycin for empiric therapy against infections caused by C. striatum,
although more studies are necessary to confirm these results. In any case appropriate antimi-
crobial therapy against C. striatum infections must be prescribed on the basis of the data pro-
vided by antibiotic susceptibility tests for each strain.
Detection and mapping of aminoglycoside resistance genes
Inactivation by enzymatic modification is the most prevalent mechanism of resistance of cory-
nebacteria to aminoglycosides in the clinical setting. The aph(3’)-Ic gene, encoding an amino-
glycoside-O-phosphotransferase conferring resistance to kanamycin, neomycin,
paromomycin, ribostamycin and lividomycin, is part of plasmids and transposons and its wide
distribution includes Corynebacterium spp. [14]. Twenty-six out of the 27 C. striatum resistant
to kanamycin rendered the expected 0.48-kb amplicon when amplified with aph(3’)-Ic specific
primers. The isolate C. striatum CS3253 (MIC of kanamycin > 256 mg/L) was not amplified,
suggesting that resistance is mediated by allelic variants of the gene or by another mechanism.
The 37 C. striatum susceptible to kanamycin were negative when they were analysed by PCR-
Table 1. Susceptibility of 64 Corynebacterium striatum strains to six aminoglycosides.
Number of strains
Range MIC50(mg/L) MIC90(mg/L) Resistant Intermediate Total susceptible
Amikacin 0.016–256 0.25 0.5 0 0 64
Gentamicin 0.064–1024 2 8 45 0 19
Kanamycin 0.016–256 0.5 >256 27 0 37
Netilmicin 0.016–256 0.094 0.38 0 0 64
Streptomycin 0.064–1024 24 >1024 36 9 19
Tobramycin 0.064–1024 4 16 45 0 19
MIC, minimum inhibitory concentration; MIC50/90, MIC that inhibits 50% and 90% of the isolates, respectively.
doi:10.1371/journal.pone.0167856.t001
Table 2. Resistance phenotypes of the 52 C. striatum strains resistant to aminoglycosides.
Resistance Phenotype Number of C. striatum strains
Kan 1
Sm 7
Genta-Tob 13
Genta-Tob-Sm 5
Kan-Genta-Tob 2
Kan-Genta-Tob-Sm 24
Resistance was defined in accordance with European Committee on Antimicrobial Susceptibility Testing
(EUCAST) guidelines. Kan: kanamycin; Sm: streptomycin; Genta: gentamicin; Tob: tobramycin.
doi:10.1371/journal.pone.0167856.t002
Susceptibility to Aminoglycosides in Corynebacterium striatum
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aph(3’)-Ic. Therefore, in our C. striatum, there is a correlation between resistance to kanamycin
and the presence of the aph(3’)-Ic gene. As kanamycin is not prescribed in Spain, the high
prevalence of this gene in C. striatum may be due to its genetic linkage with other resistance
genes (see below).
In Corynebacterium spp., the main mechanism of streptomycin resistance is related to the
presence of the tandem of genes aph(3”)-Ib and aph(6)-Id, encoding for aminoglycoside-3”-
phosphotransferase [APH (3”)-Ib] and aminoglycoside-6-phosphotransferase [APH (6)-Id],
respectively [14]. Thirty-six out of our 64 C. striatum were streptomycin resistant. In 23 strep-
tomycin resistant C. striatum PCR amplification resulted in the expected aph(3”)-Ib (0.55 Kb)
and aph(6)-Id (0.51 Kb) amplicons. However, twelve out of the 24 C. striatum streptomycin
resistant isolates did not give aph(3”)-Ib neither aph(6)-Id amplicons, suggesting that in these
strains streptomycin resistance is mediated by allelic variants of these genes or by another
mechanism. One C. striatum (CS6865) was susceptible to streptomycin (MIC = 1 mg/L) but
gave the aph(3”)-Ib and aph(6)-Id amplicons, which might be due to mutations affecting the
aph(3”)-Ib-aph(6)-Id genes or their promoter region.
Forty-four out of 64 C. striatum were positive for the gene aac(3)-XI, encoding AAC(3)-XI,
a new aminoglycoside 3-N acetyl transferase from C. striatum [15]. AAC (3)-XI acetyl transfer-
ase confers resistance to gentamicin, tobramycin, sisomicin, dibekacin and fortimicin. The
44 C. striatum carrying the aac(3)-XI gene showed MICs of both gentamicin and tobramycin
> 1 mg/L. Nineteen out the 20 isolates negative for the aac(3)-XI gene were susceptible to both
gentamicin and tobramycin (MICs < 0.064 mg/L) whereas one isolate showed a MIC = 1.5
mg/L for both compounds. Therefore, there is a good correlation between resistance to these
two compounds and the presence of the aac(3)-XI gene.
The 44 isolates positive for the gene aac(3)-XI have a gentamicin MIC range of 1–16 mg/L,
supporting the EUCAST clinical breakpoint of> 1 mg/L. If the gentamicin breakpoint recom-
mended by the CLSI was used (>16 mg/L) [16], most of the isolates positive for the aac(3)-XI
gene are not considered as resistant. This difference in interpretation between the European
and the US recommendations could result in an underestimate of gentamicin resistant C. stria-
tum if the CLSI breakpoint instead of the EUCAST breakpoint was used, with possible serious
consequences for patients.
In order to know the genomic context of the aminoglycoside resistance genes and inquiry
about their transfer mechanisms we sequenced the genome of the isolate C. striatum CS4933,
which was chosen for its clinical relevance (it was isolated from soft tissue abscess) and its
resistance profile (it was resistant to kanamycin and streptomycin). Annotation of the genome
sequence of C. striatum CS4933 revealed that the aph(3’)-Ic gene is flanked by two divergently
oriented IS26-like elements (Fig 1), forming a new transposon similar to Tn5715 but with the
aph(3’)-Ic gene and the IS26 modules inversely oriented [17]. The aph(3’)-Ic gene is part of a
larger DNA region containing the aph(3”)-Ib—aph(6)-Id tandem pair of resistance genes con-
ferring streptomycin resistance. The aph(3”)-Ib—aph(6)-Id coding regions of C. striatum
CS4933 are located downstream of the resolvase gene from a Tn5393-like transposon that is
disrupted by the Tn5715 element containing the aph(3’)-Ic gene. Essentially identical amino-
glycoside resistance regions were found in the plasmid pTP10 from C. striatum [17], in the
chromosome of C. urealyticum DSM1709 [18] and in the plasmid pJA144188 of C. resistens
DSM 45100 [19] (Fig 1).
Molecular epidemiology of the C. striatum isolates
The PFGE method displayed a high tipability (100% of the isolates were clearly assigned to one
pulsotype), and discriminatory power. PFGE delineated the 64 C. striatum isolates into forty-
Susceptibility to Aminoglycosides in Corynebacterium striatum
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six distinct PFGE types (Fig 2). On these, PFGE types 3, 8, 34 and 46 could be further classified
into 2 subtypes. Most PFGE patterns corresponded to single isolates, whereas one PFGE pat-
tern was observed for 7 isolates, 3 patterns contained three isolates each, and 6 patterns two
isolates each. The dendrogram showed a Dice similarity coefficient ranging from 63 to 97%
(Fig 2).
Most of the pulsotypes include strains showing the same resistance properties. The 3 strains
of the PFGE type 4 were resistant to streptomycin and positive for the genes aph(3”)-Ib and
aph(6)-Id, whereas the 3 strains of the type 23 were sensitive to all aminoglycosides. The 3
strains of the pulsotype 28 were resistant to four aminoglycosides (kanamycin, streptomycin,
gentamicin and tobramycin) and contain the aph(3’)-Ic, aph(3”)-Ib, aph(6)-Id and aac(3)-XI
genes.
High number of pulsotypes in C. striatum indicated a high genetic diversity in this species.
PFGE analysis revealed that our 64 C. striatum are mostly unrelated, producing sporadic
infections.
Fig 1. Genomic context of the aminoglycoside resistance genes. Maps of the region including aph(3’)-Ic, aph(3”)-Ib and aph(6)-Id genes of C. striatum
CS4933, C. striatum plasmid pTP10 [17], C. urealyticum DSM1709 [18] and C. resistens plasmid pJA144188 [19].
doi:10.1371/journal.pone.0167856.g001
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